For the risk stratification of indeterminate thyroid nodules

Blog
Contact Us
Payment
Physician Portal

Please visit us at ENDOExpo 2024 (Booth 626)

Visit Us at the ATA 2026 Annual Meeting—Booth #48

View Observational Study

Go Now
Back to Evidence
  • IIT Studies

Morand GB, et al. Molecular alteration patterns predict tumor behavior in papillary thyroid carcinoma independent of tumor size: insights from an international multicenter retrospective study. Thyroid Res. 2025;18(1):14. doi:10.1186/s13044-025-00231-0

Molecular alteration patterns were demonstrated to provide an accurate prediction of tumor behavior in papillary thyroid carcinoma (PTC) compared to tumor size alone. The study involved 718 patients who underwent preoperative molecular profiling, with ThyGenX®/ThyGeNEXT® (66.6%) or ThyroSeq V3 (33.4%).

The molecular tests classified thyroid nodules into distinct molecular patterns: BRAF-like (31.6%), RAS-like (23.8%), and non-BRAF-non-RAS (NBNR) (8.2%). Notably, nodules with BRAF-like molecular alterations were more likely to have exhibited extrathyroidal extension (ETE) compared to those with RAS-like or NBNR alterations (p<0.001), despite smaller tumor sizes (13mm versus 17mm for RAS-like and 18mm for NBNR).

No significant correlation between tumor size and aggressive features, such as extrathyroidal extension or nodal metastasis (p>0.05) was found. This study reinforces the value of molecular profiling to help inform treatment strategies and potentially reduce patient anxiety through improved prognostication.

View Paper

Patient management decisions are based on the independent medical judgment of the physician and molecular test results should be taken into consideration in conjunction with all relevant imaging, clinical findings, patient and family history, as well as patient preference.

Back to Clinical Studies
  • IIT Studies

Morand GB, et al. Molecular alteration patterns predict tumor behavior in papillary thyroid carcinoma independent of tumor size: insights from an international multicenter retrospective study. Thyroid Res. 2025;18(1):14. doi:10.1186/s13044-025-00231-0

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

View Paper

Patient management decisions are based on the independent medical judgment of the physician and molecular test results should be taken into consideration in conjunction with all relevant imaging, clinical findings, patient and family history, as well as patient preference.